<DOC>
	<DOCNO>NCT02963831</DOCNO>
	<brief_summary>This two-part Phase 1/2 dose escalation dose expansion study GMCSFencoding adenovirus , ONCOS-102 , combination anti-programmed death ligand-1 ( PDL1 ) antibody , durvalumab , adult subject peritoneal disease fail prior standard chemotherapy histologically confirm platinum-resistant refractory epithelial ovarian cancer colorectal cancer .</brief_summary>
	<brief_title>A Phase 1/2 Study Investigate Safety , Biologic Anti-tumor Activity ONCOS-102 Combination With Durvalumab Subjects With Advanced Peritoneal Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Subjects peritoneal disease fail prior standard chemotherapy histologic confirmation platinumresistant refractory epithelial ovarian cancer , fallopian tube cancer , primary peritoneal cancer , endometrial cancer , cervical cancer , vaginal vulvar cancer , uterine sarcoma include leiomyosarcoma , carcinosarcoma high grade endometrial stromal sarcoma , gastroesophageal cancer , pancreatic cancer , cholangiocarcinoma , colorectal cancer , gastrointestinal neuroendocrine tumor , mesothelioma enrol . 2 . The subject willing undergo core needle biopsy screen Cycle 2 , Study Week 5 . Archival tumor sample request , require eligibility . 3 . Previously treat advanced cancer additional therapy option available know prolong survival . 4 . Laboratory parameter vital function normal range clinically significant . 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status â‰¤ 1 1 . Treatment investigational agent within 4 week start study treatment prior treatment checkpoint inhibitor ( cytotoxic Tlymphocyteassociated protein 4 ( CTLA4 ) , program cell death protein 1 ( PD1 ) program death ligand 1 ( PDL1 ) antibody ) . 2 . Subjects know active central nervous system metastasis , glioma nervous system malignancy include carcinomatous meningitis invasive malignancy within 5 year except noninvasive malignancy cervical carcinoma situ , nonmelanomatous carcinoma skin ductal carcinoma situ breast has/have surgically cure . 3 . Known immunodeficiency know evidence acute chronic human immunodeficiency virus ( HIV ) , Hepatitis B , Hepatitis C uncontrolled intercurrent illness . 4 . Ongoing bowel perforation presence bowel fistula abscess history small large bowel obstruction within 3 month registration , include subject palliative gastric drainage catheter . Subjects palliative divert ileostomy colostomy allow symptomfree 3 month . 5 . Subjects clinically significant cardiovascular disease , history organ transplant allogeneic bone marrow transplant , active know history autoimmune disease might recur major surgery within 28 day prior first dose still recover prior surgery .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Oncos-102</keyword>
	<keyword>Durvalumab</keyword>
	<keyword>Peritoneal</keyword>
	<keyword>Cyclophosphamide</keyword>
</DOC>